Table 3.

Comparison of characteristics of infants with confirmed late intracranial VKDB admitted to a PICU in the Netherlands under the 25-μg and 150-μg oral prophylactic regimens

	25 μg: January 2008–February 2011	150 μg: March 2011–December 2015	p value
Feature
Male/female, N (%)	9 (50)/9 (50)	8 (80)/2 (20)	0.226
Birth weight, mean (range), g	3496 (2830–4245)	3352 (2510–4000)	0.509
Age at diagnosis, mean (range), days	45 (28–97)	54 (21–101)	0.337
Weight at diagnosis, mean (range), g	4428 (3170–5500)	4681 (3400–5600)	0.358
Biochemical parameters
Bilirubin total, median (range), μmol/l	81 (26–242)	77 (45–246)	0.792
Bilirubin direct, median (range), μmol/l	44 (8–131)	59 (23–206)	0.482
ASAT, median (range), U/l	68 (20–399)	96 (40–526)	0.350
ALAT, median (range), U/l	45 (15–232)	53 (21–224)	0.415
Etiology
Exclusively breastfed, N (%)	18 (100)	8 (80)	0.150
Cholestasis, N (%)	14 (78)	8 (80)	0.625
Underlying disorder, N (%)	12 (67)	7 (70)	1.000
Inadequate administration, N (%)	4 (22)	2 (20)	1.000
Short-term outcome
MRPIM2, median (P25-P75)	0.17 (0.03–0.29)	0.06 (0.04–0.23)	0.532
Neurosurgical intervention, N (%)	7 (39)	3 (30)	0.703
Mechanical ventilation, N (%)	14 (78)	7 (70)	0.674
Duration of mechanical ventilation, median (range), days	4 (1–13)	4 (2–12)	0.771
Length of stay at a PICU, median (range), days	4 (1–15)	5 (2–15)	0.551
Long-term outcome
Died, N (%)	5 (28)	4 (40)	0.677
Neurological sequelae, N (%)	3 (17)	2 (20)	0.635

VKDB vitamin K deficiency bleeding, PICU pediatric intensive care unit, N number, ASAT asparagine aminotransferase, ALAT alanine aminotransferase, MRPIM2 pediatric index of mortality: mortality rate